Market Movements - U.S. stock index futures are all up, with Dow futures rising by 0.65%, S&P 500 futures up by 0.81%, and Nasdaq futures increasing by 1.09% [1] - European indices also show positive movement, with Germany's DAX up by 1.35%, UK's FTSE 100 up by 0.29%, France's CAC40 up by 1.23%, and the Euro Stoxx 50 up by 1.55% [1] - WTI crude oil is up by 0.34%, priced at $64.27 per barrel, while Brent crude oil is up by 0.28%, priced at $68.14 per barrel [1][2] Market News - Small-cap stocks are regaining focus as expectations for Federal Reserve rate cuts rise, with the Russell 2000 index rising by 2.1% to 2453.36 points, marking its first breach of the historical closing high since November 2021 [3] - Despite the Fed's rate cut, market volatility is expected to increase due to uncertainty about future rate cuts, with significant internal disagreements within the Fed regarding policy outlook for 2026 [4] Corporate News - 71% of U.S. CEOs express concerns that tariffs are damaging businesses, highlighting frustrations with the current business environment during a closed-door meeting at Yale [5] - Deutsche Bank raises its forecast for the average gold price in 2026 to $4000 per ounce, citing continued demand from central banks and the impact of Fed rate cuts [5] Individual Stocks - Novo Nordisk's stock jumps nearly 7% after its diabetes drug Ozempic shows superior cardiovascular protection compared to Eli Lilly's Trulicity, with a 23% lower risk of heart attack, stroke, or death for Ozempic users [6] - FedEx's upcoming earnings report is seen as a critical indicator for the sustainability of the current bull market, amid concerns over the divergence between industrial and transportation indices [6] - Bullish reports a significant earnings increase, with Q2 EPS at $0.93, surpassing market expectations, and shares rise nearly 9% [7] - Palantir commits to investing £1.5 billion in the UK and secures a £750 million contract with the UK Ministry of Defence [7] - Roche acquires 89bio for up to $3.5 billion to expand into the weight loss drug market, with 89bio's key drug targeting metabolic diseases [8][9] - Arvinas partners with Pfizer to commercialize a breast cancer drug, with shares rising over 2% [9]